{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:24:53Z","timestamp":1753273493374,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00280-024-04696-y","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T09:02:16Z","timestamp":1723021336000},"page":"549-559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19"],"prefix":"10.1007","volume":"94","author":[{"given":"Ming","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1782-6709","authenticated-orcid":false,"given":"Yizhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-8927","authenticated-orcid":false,"given":"Ken","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian James","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1701-492X","authenticated-orcid":false,"given":"Lu","family":"Gaohua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"4696_CR1","unstructured":"Bristol Myers Squibb (2023) Inrebic\u00ae (fedratinib) prescribing information. https:\/\/packageinserts.bms.com\/pi\/pi_inrebic.pdf. Accessed 20 Mar 2024"},{"key":"4696_CR2","unstructured":"European Medicines Agency Inrebic\u00ae (fedratinib) [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb (2024) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inrebic-epar-product-information_en.pdf. Accessed 20 Mar 2024"},{"issue":"7","key":"4696_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29(7):789\u2013796. https:\/\/doi.org\/10.1200\/JCO.2010.32.8021","journal-title":"J Clin Oncol"},{"issue":"8","key":"4696_CR4","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1038\/bcj.2015.63","volume":"5","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H, Talpaz M (2015) A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J 5(8):e335. https:\/\/doi.org\/10.1038\/bcj.2015.63","journal-title":"Blood Cancer J"},{"issue":"4","key":"4696_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00280-019-03929-9","volume":"84","author":"K Ogasawara","year":"2019","unstructured":"Ogasawara K, Zhou S, Krishna G, Palmisano M, Li Y (2019) Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. Cancer Chemother Pharmacol 84(4):891\u2013898. https:\/\/doi.org\/10.1007\/s00280-019-03929-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4696_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cpdd.161","volume":"4","author":"M Zhang","year":"2015","unstructured":"Zhang M, Xu C, Ma L, Shamiyeh E, Yin J, von Moltke LL, Smith WB (2015) Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): results from two phase I studies in healthy volunteers. Clin Pharmacol Drug Dev 4(4):315\u2013321. https:\/\/doi.org\/10.1002\/cpdd.161","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"4696_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/jcph.218","volume":"54","author":"M Zhang","year":"2014","unstructured":"Zhang M, Xu CR, Shamiyeh E, Liu F, Yin JY, von Moltke LL, Smith WB (2014) A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. J Clin Pharmacol 54(4):415\u2013421. https:\/\/doi.org\/10.1002\/jcph.218","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4696_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00280-020-04121-0","volume":"86","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, Xu C, Kanamaluru V, Siebers N, Surapaneni S, Ridoux L, Palmisano M, Krishna G (2020) Excretion balance and pharmacokinetics following a single oral dose of [(14)C]-fedratinib in healthy subjects. Cancer Chemother Pharmacol 86(2):307\u2013314. https:\/\/doi.org\/10.1007\/s00280-020-04121-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4696_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00280-020-04131-y","volume":"86","author":"F Wu","year":"2020","unstructured":"Wu F, Krishna G, Surapaneni S (2020) Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib. Cancer Chemother Pharmacol 86(4):461\u2013473. https:\/\/doi.org\/10.1007\/s00280-020-04131-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"4696_CR10","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/psp4.12706","volume":"10","author":"D Jean","year":"2021","unstructured":"Jean D, Naik K, Milligan L, Hall S, Mei Huang S, Isoherranen N, Kuemmel C, Seo P, Tegenge MA, Wang Y, Yang Y, Zhang X, Zhao L, Zhao P, Benjamin J, Bergman K, Grillo J, Madabushi R, Wu F, Zhu H, Zineh I (2021) Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision-making-A workshop summary. CPT Pharmacometrics Syst Pharmacol 10(11):1271\u20131275. https:\/\/doi.org\/10.1002\/psp4.12706","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"4696_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cpt.37","volume":"97","author":"HM Jones","year":"2015","unstructured":"Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD (2015) Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther 97(3):247\u2013262. https:\/\/doi.org\/10.1002\/cpt.37","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"4696_CR12","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1002\/jcph.1767","volume":"60","author":"X Zhang","year":"2020","unstructured":"Zhang X, Yang Y, Grimstein M, Fan J, Grillo JA, Huang SM, Zhu H, Wang Y (2020) Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018\u20132019 submissions to the US FDA\u2019s Office of Clinical Pharmacology. J Clin Pharmacol 60(Suppl 1):S160\u2013s178. https:\/\/doi.org\/10.1002\/jcph.1767","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"4696_CR13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00280-020-04067-3","volume":"85","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, Xu C, Kanamaluru V, Palmisano M, Krishna G (2020) Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects. Cancer Chemother Pharmacol 85(5):899\u2013906. https:\/\/doi.org\/10.1007\/s00280-020-04067-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4696_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00280-022-04464-w","volume":"90","author":"Y Chen","year":"2022","unstructured":"Chen Y, Ogasawara K, Wood-Horrall R, Thomas M, Thomas M, He B, Liu L, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G (2022) Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults. Cancer Chemother Pharmacol 90(4):325\u2013334. https:\/\/doi.org\/10.1007\/s00280-022-04464-w","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4696_CR15","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00280-020-04074-4","volume":"85","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, Vince B, Xu C, Zhang M, Palmisano M, Krishna G (2020) A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects. Cancer Chemother Pharmacol 85(5):995\u20131001. https:\/\/doi.org\/10.1007\/s00280-020-04074-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4696_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00280-020-04102-3","volume":"86","author":"K Ogasawara","year":"2020","unstructured":"Ogasawara K, LoRusso PM, Olszanski AJ, Rixe O, Xu C, Yin J, Palmisano M, Krishna G (2020) Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer Chemother Pharmacol 86(1):87\u201395. https:\/\/doi.org\/10.1007\/s00280-020-04102-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"4696_CR17","unstructured":"Simcyp (2021) V19R1_V20R1_VersionComparison. Simcyp Resource"},{"issue":"6","key":"4696_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/dmd.115.066845","volume":"44","author":"LM Almond","year":"2016","unstructured":"Almond LM, Mukadam S, Gardner I, Okialda K, Wong S, Hatley O, Tay S, Rowland-Yeo K, Jamei M, Rostami-Hodjegan A, Kenny JR (2016) Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model. Drug Metab Dispos 44(6):821\u2013832. https:\/\/doi.org\/10.1124\/dmd.115.066845","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"4696_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejps.2009.12.002","volume":"39","author":"K Rowland Yeo","year":"2010","unstructured":"Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39(5):298\u2013309. https:\/\/doi.org\/10.1016\/j.ejps.2009.12.002","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"4696_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1586\/ecp.13.4","volume":"6","author":"KR Yeo","year":"2013","unstructured":"Yeo KR, Jamei M, Rostami-Hodjegan A (2013) Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol 6(2):143\u2013157. https:\/\/doi.org\/10.1586\/ecp.13.4","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"4696_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00280-021-04292-4","volume":"88","author":"K Ogasawara","year":"2021","unstructured":"Ogasawara K, Kam J, Thomas M, Liu L, Liu M, Xue Y, Surapaneni S, Carayannopoulos LN, Zhou S, Palmisano M, Krishna G (2021) Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants. Cancer Chemother Pharmacol 88(3):369\u2013377. https:\/\/doi.org\/10.1007\/s00280-021-04292-4","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04696-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04696-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04696-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T04:02:53Z","timestamp":1727496173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04696-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["4696"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04696-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All trials described were conducted in compliance with the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use\/Good Clinical Practice and applicable regulatory requirements. Trial protocols were submitted to an independent review board for review and written approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent to participate in the trials described.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors read and approved publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors (MC, YC, KO, BJS, and LG) are employees and stockholders of Bristol Myers Squibb.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}